Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib + Trastuzumab in HER2+ Metastatic Colorectal Cancer
NCT03843749Phase 2Unknown
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Jul 2019
- Primary completion
- Jul 2019
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of pyrotinib in colorectal cancer (CRC), sponsored by Shanghai Changzheng Hospital. Status: unknown.
02
Drugs
pyrotinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03843749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03843749.